Cargando…

Cost-Effectiveness of Early Treatment with Originator Biologics or Their Biosimilars After Methotrexate Failure in Patients with Established Rheumatoid Arthritis

INTRODUCTION: Evidence supports the clinical benefits of early aggressive biologic treatment in patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but the cost-effectiveness of early intervention with or...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patel, Dipen, Shelbaya, Ahmed, Cheung, Raymond, Aggarwal, Jyoti, Park, Sang Hee, Coindreau, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822985/ https://www.ncbi.nlm.nih.gov/pubmed/31148057 http://dx.doi.org/10.1007/s12325-019-00986-7

Ejemplares similares

Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
por: Fleischmann, Roy M, et al.
Publicado: (2016)

Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity
por: Huizinga, Tom W. J., et al.
Publicado: (2020)

Nano Methotrexate versus Methotrexate in Targeting Rheumatoid Arthritis
por: Salem, Heba F., et al.
Publicado: (2022)

Real‐World Adherence to Oral Methotrexate Measured Electronically in Patients With Established Rheumatoid Arthritis
por: Michaud, Kaleb, et al.
Publicado: (2019)

Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
por: Mysler, Eduardo, et al.
Publicado: (2016)

Methotrexate alone and methotrexate combined with etanercept in treatment of rheumatoid arthritis
por: Rexhepi, Sylejman, et al.
Publicado: (2012)

Methotrexate Hepatotoxicity in Patients with Rheumatoid Arthritis
por: Sotoudehmanesh, R, et al.
Publicado: (2010)

Adherence to Methotrexate therapy in Rheumatoid Arthritis
por: Arshad, Nasim, et al.
Publicado: (2016)

Review of Biosimilar Trials and Data on Adalimumab in Rheumatoid Arthritis
por: Zhao, Sizheng, et al.
Publicado: (2018)

Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis
por: Chadwick, Laura, et al.
Publicado: (2018)

Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
por: Cohen, Stanley B, et al.
Publicado: (2023)

Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
por: Keystone, Edward C, et al.
Publicado: (2017)

Barriers towards effective pharmacovigilance systems of biosimilars in rheumatology: A Latin American survey
por: Castañeda‐Hernández, Gilberto, et al.
Publicado: (2019)

Efficacy of methotrexate and etanercept biosimilar rhTNFR:Fc in Chinese patients with active rheumatoid arthritis: A controlled, randomized and multicenter study
por: Wu, Qingjun, et al.
Publicado: (2020)

A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients
por: Tian, Feng, et al.
Publicado: (2019)

Prevalence of methotrexate intolerance in rheumatoid arthritis and psoriatic arthritis
por: Bulatović Ćalasan, Maja, et al.
Publicado: (2013)

Greater uptake, an alternative reimbursement methodology needed to realize cost-saving potential of oncology biosimilars in the United States
por: Yang, Jingyan, et al.
Publicado: (2021)

Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study)
por: Abraham, Bincy, et al.
Publicado: (2022)

Utilization of Subcutaneous Methotrexate in Rheumatoid Arthritis Patients After Failure or Intolerance to Oral Methotrexate: A Multicenter Cohort Study
por: Branco, Jaime C., et al.
Publicado: (2016)

Comparison of Efficacy and Safety of Original and Biosimilar Adalimumab in Active Rheumatoid Arthritis in a Real-World National Cohort
por: Popescu, Claudiu Costinel, et al.
Publicado: (2022)

Hepatic failure in a patient with rheumatoid arthritis treated with methotrexate: A case report
por: Miyata, Masayuki, et al.
Publicado: (2023)

A Cost per Responder Model for Abatacept versus Adalimumab Among Rheumatoid Arthritis Patients with Seropositivity
por: Park, Sang Hee, et al.
Publicado: (2020)

Mean cost per number needed to treat with tocilizumab plus methotrexate versus abatacept plus methotrexate in the treatment of rheumatoid arthritis in patients previously treated with methotrexate
por: Benucci, Maurizio, et al.
Publicado: (2017)

Cost-Effectiveness of Baricitinib for Patients with Moderate-to-Severe Rheumatoid Arthritis After Methotrexate Failed in China
por: Li, SiNi, et al.
Publicado: (2021)

Cost-effectiveness of Triple Therapy vs. Biologic Treatment Sequence as First-line Therapy for Rheumatoid Arthritis Patients after Methotrexate Failure
por: Li, SiNi, et al.
Publicado: (2021)

Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA
por: Kearsley-Fleet, Lianne, et al.
Publicado: (2023)

Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure
por: Kapral, Theresa, et al.
Publicado: (2006)

Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis
por: Bello, Alfonso E, et al.
Publicado: (2017)

Safety Profile of Methotrexate Therapy in Patients With Rheumatoid Arthritis
por: Mustafa, Syed Hassan, et al.
Publicado: (2022)

Rheumatoid arthritis and Hailey‐Hailey disease treated with methotrexate
por: Mestre, Beatriz, et al.
Publicado: (2022)

Efficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosage
por: Gallo, G, et al.
Publicado: (2016)

Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
por: Moots, Robert, et al.
Publicado: (2017)

Comparative Effectiveness of Tocilizumab with either Methotrexate or Leflunomide in the Treatment of Rheumatoid Arthritis
por: Narváez, Javier, et al.
Publicado: (2015)

Will savings from biosimilars offset increased costs related to dose escalation? A comparison of infliximab and golimumab for rheumatoid arthritis
por: Curtis, Jeffrey R., et al.
Publicado: (2019)

Pharmacogenomics of Methotrexate Membrane Transport Pathway: Can Clinical Response to Methotrexate in Rheumatoid Arthritis Be Predicted?
por: Lima, Aurea, et al.
Publicado: (2015)

Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis
por: Isozaki, Takeo, et al.
Publicado: (2010)

Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
por: Burmester, Gerd R, et al.
Publicado: (2017)

Replication study of polymorphisms associated with response to methotrexate in patients with rheumatoid arthritis
por: López-Rodríguez, Rosario, et al.
Publicado: (2018)

Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis
por: Lu, XiaoQin, et al.
Publicado: (2021)

Uptake of Biosimilars and Its Economic Implication for the Treatment of Patients with Rheumatoid Arthritis in Korea
por: Cho, Soo-Kyung, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cnjfr48qi660i7ri8jqb6osd6k